Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Robust biological signaling networks evolved, through gene duplications, from simple, relatively fragile cascades. Architectural features such as layered configuration, branching and modularity, as well as functional characteristics (e.g., feedback control circuits), enable fail-safe performance in the face of internal and external perturbations. These universal features are exemplified here using the receptor tyrosine kinase (RTK) family. The RTK module is richly mutated and overexpressed in human malignancies, and pharmaceutical interception of its signaling effectively retards growth of specific tumors. Therapy-induced interception of RTK-signaling pathways and the common evolvement of drug resistance are respectively considered here as manifestations of fragility and plasticity of robust networks. The systems perspective we present views pathologies as hijackers of biological robustness and offers ways for identifying fragile hubs, as well as strategies to overcome drug resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Network biology: understanding the cell's functional organization
Barabási, A.-L., & Oltvai, Z. N. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1272 · Cited by 7,903
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974 · cited 2×
“…of RTKs are frequently identified in human tumors (Blume-Jensen and Hunter, 2001), and second, pharmaceutical targeting of RTKs, such as the epidermal growth factor receptor (EGFR) and its sibling, HER2, can retard tumor growth, primarily in the case of carcinomas (Yarden and Sliwkowski, 2001).”
BackgroundSelf-citationThe Evolutionary Fate and Consequences of Duplicate Genes
Lynch, M., & Conery, J. S. (2000) · Science · doi:10.1126/science.290.5494.1151 · Cited by 4,988 · cited 2×
“01 duplications per gene in million years (Lynch and Conery, 2000), and in punctated large-scale events.”
BackgroundInfluentialBlume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 2×
“For example, only one-third of HER2-overexpressing mammary tumors respond to trastuzumab (primary resistance), and patients who initially respond to mAbs or to TKIs often relapse due to evolvement of secondary resistance”
BackgroundClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
An Introduction to Systems Biology: Design Principles of Biological Circuits
Alon, U. (2006) · doi:10.1201/9781420011432 · Cited by 2,825
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 2×
“…of molecular mechanisms enable mAbs to inhibit cancer cell growth: immune mechanisms involving ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC; Clynes et al, 2000) and a variety of non-immune mechanisms that intercept tumorigenesis, including triggering of mitochondria-mediated apoptosis,…”
BackgroundHunter, T. (2000) · Cell · doi:10.1016/s0092-8674(00)81688-8 · Cited by 2,586
Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences
Downward, J., Yarden, Y., Mayes, E., Scrace, G., Totty, N., Stockwell, P., Ullrich, A., Schlessinger, J., & Waterfield, M. D. (1984) · Nature · doi:10.1038/307521a0 · Cited by 2,516
Self-citationKitano, H. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1471 · Cited by 2,278
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858 · cited 1×
“Thus, the kinomes of nematodes, flies, sea urchins and urochordates contain, respectively, 12, 18, 19 and 16 RTKs (Tan and Kim, 1999; Morrison et al, 2000; Bradham et al, 2006), but the kinomes of mammals contain 58 RTKs.”
BackgroundAn allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Zhang, X., Gureasko, J., Shen, K., Cole, P. A., & Kuriyan, J. (2006) · Cell · doi:10.1016/j.cell.2006.05.013 · Cited by 1,650 · cited 3×
“According to a recent study, the C-lobe of one kinase domain is juxtaposed next to the N-lobe of the other (Zhang et al, 2006).”
BackgroundCell-signalling dynamics in time and space
Kholodenko, B. N. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1838 · Cited by 1,347
Robustness of cellular functions
Stelling, J., Sauer, U., Szallasi, Z., Doyle, F. J., & Doyle, J. (2004) · Cell · doi:10.1016/j.cell.2004.09.008 · Cited by 1,049
Lau, L. F., & Nathans, D. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.5.1182 · Cited by 856
Phosphotyrosine interactome of the ErbB‐receptor kinase family
Schulze, W. X., Deng, L., & Mann, M. (2005) · Molecular Systems Biology · doi:10.1038/msb4100012 · Cited by 753
A positive-feedback-based bistable ‘memory module’ that governs a cell fate decision.
Xiong, W., & Ferrell, J. E. (2003) · Nature · doi:10.1038/nature02089 · Cited by 741
Biological networks: the tinkerer as an engineer
Alon, U. (2003) · Science · doi:10.1126/science.1089072 · Cited by 706 · cited 1×
“Further, modularity enables reutilization of genetic circuits in different biological settings, adaptation to rapidly changing environments (Alon, 2003), as well as the generation of new cell lineages (Tautz, 2000; Alon, 2006).”
BackgroundInsect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity.
Guy, P. M., Platko, J. V., Cantley, L. C., Cerione, R. A., & Carraway, K. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.17.8132 · Cited by 698 · cited 2×
“The N-terminal lobe of the kinase domain comprises beta-strands and a single alpha-helix, whereas the C-terminal lobe is composed mainly of alpha-helices, which nest ATP in a cleft defined by the two lobes (Hubbard and Till, 2000).”
BackgroundBow ties, metabolism and disease
Csete, M., & Doyle, J. (2004) · Trends in biotechnology · doi:10.1016/j.tibtech.2004.07.007 · Cited by 468
The evolution of signalling pathways in animal development
Pires-daSilva, A., & Sommer, R. J. (2003) · Nature Reviews Genetics · doi:10.1038/nrg977 · Cited by 466 · cited 3×
“The list of major pathways includes G protein-coupled receptors, nuclear hormone receptors, transforming growth factor beta, Notch, Janus kinase (JAK), Hedgehog, Wingless-related and receptor tyrosine kinases (RTKs) (Pires-daSilva and Sommer, 2003).”
BackgroundCancer as a robust system: implications for anticancer therapy
Kitano, H. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1300 · Cited by 456
Klapper, L. N., Glathe, S., Vaisman, N., Hynes, N. E., Andrews, G. C., Sela, M., & Yarden, Y. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.4995 · Cited by 455 · cited 18×
“The enigma of pseudo-RTKs and the ligandless receptor, HER2 Several RTKs (e.g., RYK/VIK and KLG) belong to a group of inactive kinases, which have been termed pseudokinases (Boudeau et al, 2006).”
BackgroundInfluentialSelf-citationCancer: A Systems Biology disease
Hornberg, J. J., Bruggeman, F. J., Westerhoff, H. V., & Lankelma, J. (2006) · Biosystems · doi:10.1016/j.biosystems.2005.05.014 · Cited by 381 · cited 2×
“Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy”
BackgroundUnder cover: causes, effects and implications of Hsp90‐mediated genetic capacitance
Sangster, T. A., Lindquist, S., & Queitsch, C. (2004) · BioEssays · doi:10.1002/bies.20020 · Cited by 251 · cited 1×
“The molecular basis of tolerance includes chaperone proteins that refold mildly mutated client proteins (Sangster et al, 2004).”
Background
Cited by
The ERBB network: at last, cancer therapy meets systems biology
Yarden, Y., & Pines, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3309 · Cited by 988
Self-citationErbB receptors and signaling pathways in cancer
Hynes, N. E., & MacDonald, G. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.010 · Cited by 956
“However, it is likely that there are also differences since the usual negative regulatory loops that function in normal cells are impaired [24].”
BackgroundDrug development of MET inhibitors: targeting oncogene addiction and expedience
Comoglio, P. M., Giordano, S., & Trusolino, L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2530 · Cited by 818
Endocytosis and signaling: Cell logistics shape the eukaryotic cell plan
Sigismund, S., Confalonieri, S., Ciliberto, A., Polo, S., Scita, G., & Di Fiore, P. P. (2012) · Physiological Reviews · doi:10.1152/physrev.00005.2011 · Cited by 338
“VPS13B 1 (48) 2 (23) 3 (11) 6 (7) 1 (2) 4 (6) 17 X”
BackgroundSahin, Ö., Fröhlich, H., Löbke, C., Korf, U., Burmester, S., Majety, M., Mattern, J., Schupp, I., Chaouiya, C., Thieffry, D., et al. (2009) · BMC Systems Biology · doi:10.1186/1752-0509-3-1 · Cited by 335
Metadata
- Authors
- Amit, I., Wides, R., & Yarden, Y.
- Venue
- Molecular Systems Biology
- Published
- 2007-01
- Volume
- 3
- Issue
- 1
- Pages
- 151-151
- ISSN
- 1744-4292 (ISSN-L)
- OpenAlex
- W2169625143
- Cited by
- 142
- References
- 26
- FWCI
- 5.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.